All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
Bookmark this article
During the 17th International Conference on Malignant Lymphoma (ICML), the Lymphoma Hub spoke with Hervé Tilly, Centre Henri-Becquerel and University of Rouen, Rouen, FR. We asked, Is Pola-R-CHP (polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin, and prednisolone) effective and safe in elderly patients with diffuse large B-cell lymphoma (DLBCL)?
POLARIX trial: Is Pola-R-CHP effective and safe in elderly patients with DLBCL?
Polatuzumab vedotin in combination with R-CHP was granted FDA approval for patients with untreated DLBCL in April this year. Tilly discusses results from a subgroup analysis of the POLARIX trial (NCT03274492), reviewing efficacy and safety in elderly patients with DLBCL. He focuses on the primary endpoints and important adverse events.
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Phase II study of lenalidomide and R-CHOP in patients with diffuse large B-cell lymphoma
Diffuse large B-cell lymphoma (DLBCL) is recognized to be a molecularly heterogenous malignancy. Of the three main subtypes, the activated B-cell-like (ABC)...
Polatuzumab vedotin for naive DLBCL: Results from a phase 1b-2 trial
The primary objective of this ongoing, multicenter, open-label, non-randomized, phase Ib-II trial was treatment safety and tolerability, as well as the determination of the maximum...
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox